Ascendis Pharma Files Routine 6-K
Ticker: ASND · Form: 6-K · Filed: Jan 13, 2025 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, 6-K, routine-disclosure
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a routine 6-K, no major news.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on January 13, 2025, to report information as a foreign private issuer. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure.
Why It Matters
This filing indicates Ascendis Pharma A/S is fulfilling its reporting obligations as a foreign private issuer with the SEC, which is standard practice for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material information or financial updates.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (dollar_amount) — SEC File Number
- 333-203040 (dollar_amount) — Form S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is filed by Ascendis Pharma A/S as a report of a foreign private issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of January 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma file annual reports under Form 20-F?
Yes, the filing indicates Ascendis Pharma A/S files annual reports under cover of Form 20-F.
What is the SEC file number for Ascendis Pharma?
The SEC file number for Ascendis Pharma A/S is 001-36815.
Are there any specific operational updates or financial figures in this filing?
No, this Form 6-K appears to be a routine disclosure and does not contain specific operational updates or financial figures.
Filing Stats: 1,306 words · 5 min read · ~4 pages · Grade level 16.2 · Accepted 2025-01-13 06:03:51
Key Financial Figures
- $100 million — 2024 revenue of ~364 million Includes $100 million Novo Nordisk milestone payment as non-p
Filing Documents
- d906180d6k.htm (6-K) — 30KB
- 0001193125-25-004900.txt ( ) — 31KB
Forward-Looking Statements
Forward-Looking Statements This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding Ascendis future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) planned regulatory submissions for TransCon CNP and TransCon hGH, (ii) expected full-year 2024 SKYTROFA, YORVIPATH and total revenues, (iii) the PDUFA date of the supplemental BLA for SKYTROFA for the treatment of adults with growth hormone deficiency and Ascendis plans for a U.S. commercial launch, if approved, (iv) Ascendis expectations regarding the commercial launch of YORVIPATH in additional Europe Direct Countries, (v) the timing of topline results from the Phase 2 COACH Trial of TransCon CNP, (vi) Ascendis expectations regarding its TransCon protein degrader platform and first TransCon degrader product candidate, and (vii) the expected payment from Novo Nordisk. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis products and product candidates; unforeseen safety or efficacy results in Ascendis development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis development programs; unforeseen
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: January 13, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer